As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.